<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20170404033202N9</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-03-12</date_registration>
      <primary_sponsor>Sabzevar University of Medical Sciences</primary_sponsor>
      <public_title>Monitoring and comparison of fluctuations in blood oxygen saturation in two methods of induction of anesthesia by priming and succinylcholine in patients undergoing appendectomy</public_title>
      <acronym></acronym>
      <scientific_title>Monitoring and comparison of fluctuations in blood oxygen saturation in two methods of induction of anesthesia by priming and succinylcholine in patients undergoing appendectomy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-11-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/59695</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be selected at random using the most available people for the study. Each person was given a code A or B at random (sheet or envelope) and treatment was performed based on it (group A was intervention and group B was control), Blinding description: This study will be performed as a two-way blind, in which the patient and the evaluating physician are blinded to the patient group so that the patient knows the plan but does not know in which group and the physician recording the variables does not know the patient group. Depending on whether the patient is in group A (intervention) or B (control), the drugs are different.</study_design>
      <phase>3</phase>
      <hc_freetext>Comparison of fluctuations in blood oxygen levels in two methods of induction of anesthesia by priming and succinylcholine.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The group receiving succinylcholine for anesthesia.Intervention group: The group receiving succinylcholine for anesthesia in this study in both groups 0.02 mg / kg midarolam and 2 μg / kg fentanyl was given as a premedication and after three minutes in group A5 5 mg / kg sodium Thiopental is given and then scolin is given at a dose of 1.5 mg / kg and after 30 seconds the patient is intubated and then atracurium 0.5 mg / kg is administered in both groups of anesthesia with isoflurane at a dose of 2.1%. And every 45 minutes fentanyl at a dose of 1 μg / kg and atracurium at 30% of the initial dose will be repeated every 30 minutes. Intervention 2: Control group:  In this study, in both groups, 0.02 mg / kg midarolam and 2 μg / kg fentanyl were given as pre-medication and after three minutes in group B (control) after pre-medication, 10% dose of atracurium (half mg). / Kg) is prescribed for 4 minutes sodium thio pental at a rate of 5 ml / kg and the rest of the atracorium is administered and after 60 to 90 seconds of intubation is performed in both groups of anesthesia with isoflurane at a dose of 1/2 Will be and every 45 minutes fentanyl at a dose of 1 microgram / kg and atracurium will be repeated every 30 minutes at a rate of one third of the initial dose.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Nematshahi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Asadabadi Central Organization of the University</address>
        <city>Sabzevar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9613885697</zip>
        <telephone>+98 51 4422 9081</telephone>
        <email>9151737407mn@gmail.com</email>
        <affiliation>Sabzevar University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Nematshahi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Asadabadi Central Organization of the University</address>
        <city>Sabzevar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9613885697</zip>
        <telephone>+98 51 4422 9081</telephone>
        <email>9151737407mn@gmail.com</email>
        <affiliation>Sabzevar University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosed and designated appendicitis and a candidate for appendectomy
consent to participate in the evaluation
between the ages of 20 and 60 years
with ASA class 1 and 2</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Reluctance to study
Patients under 20 years and over 60 years
Patients with ASA grade equal to or greater than 3
Patients with advanced heart and lung problems</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The group receiving succinylcholine for anesthesia.Intervention group: The group receiving succinylcholine for anesthesia in this study in both groups 0.02 mg / kg midarolam and 2 μg / kg fentanyl was given as a premedication and after three minutes in group A5 5 mg / kg sodium Thiopental is given and then scolin is given at a dose of 1.5 mg / kg and after 30 seconds the patient is intubated and then atracurium 0.5 mg / kg is administered in both groups of anesthesia with isoflurane at a dose of 2.1%. And every 45 minutes fentanyl at a dose of 1 μg / kg and atracurium at 30% of the initial dose will be repeated every 30 minutes.</i_keyword>
      <i_keyword>Control group:  In this study, in both groups, 0.02 mg / kg midarolam and 2 μg / kg fentanyl were given as pre-medication and after three minutes in group B (control) after pre-medication, 10% dose of atracurium (half mg). / Kg) is prescribed for 4 minutes sodium thio pental at a rate of 5 ml / kg and the rest of the atracorium is administered and after 60 to 90 seconds of intubation is performed in both groups of anesthesia with isoflurane at a dose of 1/2 Will be and every 45 minutes fentanyl at a dose of 1 microgram / kg and atracurium will be repeated every 30 minutes at a rate of one third of the initial dose</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Measurement of blood oxygen. Timepoint: Before treatment and immediately after surgery, recovery is recorded at intervals of 10 minutes to 3 times until transfer to the ward. Method of measurement: check list.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Sabzevar University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-02-08</approval_date>
        <contact_name>Ethics committee of Sabzevar University of Medical Sciences</contact_name>
        <contact_address>Campus of University of Medical Sciences Sabzevar Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
